Management of Hypoglycemia: A High-Yield Clinical Guide

1. Introduction: Defining the Clinical Emergency

Hypoglycemia is a critical clinical emergency. While most common in patients with diabetes using insulin or secretagogues, you must maintain a high index of suspicion in non-diabetic populations to identify rare but serious underlying pathologies.

Distinguish true hypoglycemia from pseudohypoglycemia immediately to avoid unnecessary workups. True hypoglycemia is confirmed via Whipple’s triad:

1. Serum glucose < 4.0 mmol/L.

1. Presence of neuroglycopenic symptoms.

1. Rapid relief of symptoms following glucose administration.

Pseudohypoglycemia occurs when the blood glucose (BG) is > 3.9 mmol/L but the patient exhibits signs such as fatigue, headache, visual disturbances, or lightheadedness, or conversely, when the BG is < 3.9 mmol/L but the patient remains entirely asymptomatic.

2. Etiology and Pathophysiology: The Differential Diagnosis

Categorize the etiology by the presence or absence of insulin to narrow your differential.

Ward Clues: Context and Timing

• The "Seemingly Well" Patient: Suggests insulinoma or factitious use of medication.

• The Critically Ill Patient: Suggests organ failure (renal/hepatic), sepsis, or inanition.

• Fasting Hypoglycemia: Highly characteristic of an insulinoma.

• Postprandial Hypoglycemia: Suggests non-insulinoma pancreatogenous hypoglycemia or post-gastric bypass.

3. Clinical Presentation: Autonomic vs. Neuroglycopenic

Categorize symptoms to determine the severity of the crisis.

Note: The autonomic response is the body's "early warning system," triggered by the autonomic nervous system. Neuroglycopenic symptoms result directly from brain glucose deprivation; these are life-threatening signs of central nervous system fuel failure.

4. Diagnostic Investigations: Cracking the Case

When the cause is not evident, measure the following markers during a spontaneous episode or a 72-hour supervised fast:

• Plasma glucose, insulin, and proinsulin.

• C-peptide and β-hydroxybutyrate.

• Insulin antibodies and a screen for oral hypoglycemic agents (sulfonylureas/glinides).

High-Yield Clinical Clues:

• Hyperpigmentation, weight loss, and hyperkalemia: Investigate for Cortisol deficiency (Addison's disease).

• Gastrointestinal Stromal Tumor (GIST): Suspect IGF-2-mediated hypoglycemia.

• Diagnostic Glucagon Test: Inject 1.0 mg glucagon IV and measure the plasma glucose response. A significant rise distinguishes endogenous and exogenous hyperinsulinism from other causes of hypoglycemia.

High-Yield Clinical Pearl: 

The C-Peptide Utility: C-peptide is co-secreted with endogenous insulin.

• Increased C-peptide: Indicates an endogenous source. This includes insulinomas and insulin secretagogues (sulfonylureas/glinides), as these drugs stimulate the pancreas to release proinsulin.

• Decreased/Normal C-peptide: Indicates an exogenous source (e.g., factitious injected insulin).

5. Acute Management Protocols

Management is dictated by the patient's level of consciousness.

The Awake Patient (The 15-15 Rule)

• Eat 15g of rapid-acting carbohydrate (e.g., 3/4 cup of juice or 3 packets of sugar in water).

• Wait 15 minutes.

• Retest blood glucose.

• Repeat steps 1–3 until BG > 5.0 mmol/L.

• Eat the next scheduled meal. If the meal is > 1 h away, eat a snack containing 15 g of carbohydrate and a protein source.

The Unconscious or NPO Patient (Medical Emergency)

• IV Access: Administer D50W 50 mL (1 ampule) IV over 1–3 minutes.

• No IV Access: Administer 1 mg of Glucagon SC or IM.

• Initiate ongoing glucose infusion once BG exceeds 5.0 mmol/L if required.

Definitive and Adjunctive Treatments

• Insulinoma: Surgical resection is definitive. Use diazoxide if resection is not possible.

• Post-Bariatric/Non-Insulinoma: Prioritize dietary modification (small, frequent, low-carb meals). Use acarbose for severe or refractory cases.

6. Hypoglycemia Unawareness: A Critical Risk Factor

In patients with repeated episodes (typically T1DM), the autonomic "warning" response is blunted. The patient remains asymptomatic until they reach life-threatening neuroglycopenic levels.

• Risk Factors: Frequent hypoglycemia, very low A1c, autonomic neuropathy, and decreased glucagon/epinephrine responses.

• Clinical Directives: Advise the use of Medic-Alert™ bracelets and prioritize Continuous Glucose Monitors (CGMs) or flash glucose monitoring to detect falling glucose levels before symptoms (or the lack thereof) become dangerous.

Mind map of hypoglycemia

• Counter-Regulatory Hormones: Glucagon, Epinephrine, Cortisol, and Growth Hormone.

• Management Priority: Ensure Airway/Safety first. Execute parenteral glucose/glucagon for any patient with impaired consciousness.

• Diagnostic Clue: C-peptide distinguishes secretagogues and tumors (high) from injected insulin (low).

• Physical Exam Tip: Look for "tibia spots" (diabetic dermopathy) or "frozen shoulder" (adhesive capsulitis) as markers of chronic diabetes complications during your workup.

Watch our video about managing hypoglycemia